Here’s one explanation for Moderna’s $32 billion valuation
Wall Street analysts have been scraping the mathematical barrel to justify how Moderna, a company with no approved products, could be worth $32 billion based on Phase 1 vaccine data, trotting out models, maps, and imaginative spreadsheets.
STAT’s Adam Feuerstein has a more direct explanation: Moderna’s valuation reflects the U.S.’s failure to deal with the novel coronavirus.
As countries in Asia and Europe move back toward normalcy amid dwindling case counts, the U.S. has put itself in a position where only a vaccine might reverse the devastating health and economic effects of the virus. Wearing masks and staying home have proved too onerous for much of the country, shifting unprecedented attention onto Moderna and, by extension, its stock.
Read more.
STAT’s Adam Feuerstein has a more direct explanation: Moderna’s valuation reflects the U.S.’s failure to deal with the novel coronavirus.
As countries in Asia and Europe move back toward normalcy amid dwindling case counts, the U.S. has put itself in a position where only a vaccine might reverse the devastating health and economic effects of the virus. Wearing masks and staying home have proved too onerous for much of the country, shifting unprecedented attention onto Moderna and, by extension, its stock.
Read more.
No hay comentarios:
Publicar un comentario